About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Long-Term Follow-up Study of ADVM-043 | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT03804021

Long-Term Follow-up Study of ADVM-043

ADVM-043-03 is a long-term follow-up (LTFU) study of subjects who participated in the ADVM-043-01 (NCT02168686) multi-center gene therapy clinical study (ADVANCE) that evaluated ADVM-043 for the treat...

Lead sponsor: Adverum Biotechnologies, Inc.•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Adverum Biotechnologies, Inc.

ADVM-043-03 was a multi-center, observational study without administration of the ADVM-043 investigational product. Subjects who participated in the ADVANCE study (ADVM-043-01; NCT02168686) were enrolled into this LTFU study for continued safety monitoring for a 2-year period.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•The subject has A1AT deficiency and has previously received ADVM-043 gene therapy

Exclusion Criteria

•The subject is unwilling or unable to participate in all required study evaluations in the long-term follow-up protocol
•The subject is participating in another investigational treatment protocol
•The subject is unable to understand the purpose and risks of the study or cannot provide a signed and dated informed consent form (ICF)

Related studies

The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study

NCT00500123 · Alpha-1 Antitrypsin Deficiency

Enrolling By InvitationPhase 3

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

NCT02796937 · Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

Active Not RecruitingPhase 1/2

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

NCT06405633 · Alpha-1 Antitrypsin Deficiency

WITHDRAWNPhase 2

Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels

NCT02900183 · Alpha-1 Antitrypsin Deficiency

Effect Of Pulmonary Rehabilitation in Patients With Alpha-1 Antitrypsin Deficiency

NCT07242079 · Alpha-1 Antitrypsin Deficiency (AATD)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 20, 2024Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment6

Start dateDec 2018

Last updatedSep 20, 2024

Condition

Alpha-1 Antitrypsin Deficiency

Locations shown

University of Florida

Gainesville, Florida

Medical University of South Carolina

Charleston, South Carolina

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 20, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions